AstraZeneca sells European rights for schizophrenia drug to Cheplapharm

AstraZeneca Plc said on Wednesday it plans to sell the European and Russian rights for a schizophrenia drug to German firm Cheplapharm Arzneimittel for an upfront payment of $178 million, as the British drugmaker looks to offload older drugs.

from Reuters: Health News https://ift.tt/2BVMOpe